Rhemus 2006.

Study name	A double‐blind, placebo‐controlled study of a natural topical anti‐inflammatory for treatment of atopic dermatitis and psoriasis
Methods	Trial design: randomised, double‐blind study Trial registration number: not reported Country: US Outpatient or hospital, date trial conducted: not reported Duration of trial participation: 8 weeks Inclusion criteria: · Mild‐to‐moderate AD · Contralateral plaques Exclusion criteria: not reported Additional design details: to quote: "Subjects were randomized into 1 of 4 groups. Each group received the active cream, which was applied to one plaque and either hydrocortisone 1% or placebo to apply to the contralateral plaque".
Participants	Total number randomised, age, sex, ethnicity, duration of eczema, severity of eczema, body site: not reported Number of withdrawals: no results Notes: none
Interventions	Run‐in details: not reported Intervention: hydrocortisone 1.% cream · Concurrent treatment: not reported · Other key information: in the trial, TCS is one of two comparators; the other is a placebo. Comparator: vehicle/placebo · Concurrent treatment: not reported · Other key information: none Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	To quote: "Standard quantitative and qualitative assessments of atopic dermatitis were performed at baseline visit, week 2, and week 4".
Starting date	Not reported
Contact information	Not reported
Notes	Funding source: Nu Skin Enterprises Declarations of interest: not declared Original language of publication: English Other: none